Key terms

About HAE

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest HAE news

Apr 12 9:15am ET Haemonetics Poised for Growth with Strong Q4 Projections and Strategic Acquisitions Apr 04 6:32am ET Haemonetics receives FDA clearance for TEG 6s Global Hemostasis-HN cartridge Apr 01 8:12am ET Haemonetic sees Attune Medical acquisition adding $30M-$35M in revenue in FY25 Mar 19 4:55am ET Haemonetics management to meet with Oppenheimer Mar 13 4:10pm ET Haemonetics management to meet with Oppenheimer Mar 05 12:15pm ET Needham Remains a Hold on Haemonetics (HAE) Mar 05 6:02am ET Haemonetics to acquire Attune Medical for $160M upfront, sees accretion Feb 15 1:41am ET Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE), Biogen (BIIB) and Axsome Therapeutics (AXSM) Feb 13 9:20am ET Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE) and Shattuck Labs (STTK) Feb 13 5:50am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Feb 09 12:40am ET Analysts Are Bullish on Top Healthcare Stocks: Haemonetics (HAE), ALX Oncology Holdings (ALXO) Feb 08 1:05pm ET Needham Sticks to Its Hold Rating for Haemonetics (HAE) Feb 08 6:09am ET Haemonetics raises FY24 adjusted EPS view to $3.90-$4.00 from $3.75-$3.95 Feb 08 6:04am ET Haemonetics reports Q3 adjusted EPS $1.04, consensus 94c Jan 22 2:01pm ET Analysts’ Top Healthcare Picks: Petros Pharmaceuticals (PTPI), Athira Pharma (ATHA)

No recent news articles are available for HAE

No recent press releases are available for HAE

HAE Financials

1-year income & revenue

Key terms

HAE Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

HAE Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms